The Effect of the COVID-19 Pandemic on Frailty in Liver Transplant Candidates

Methodist Health System

Status: Active, not recruiting

Conditions: COVID-19; Frailty; Sarcopenia

Treatments: Behavioral: COVID Patients who Underwent pre-transplant frailty assessment (PFA) at MDMC

Study type: Observational

Funder types: Other

Identifiers

NCT05935800

012.HEP.2022.D

Details and patient eligibility

About

Frailty is associated with higher rates of morbidity, mortality, and failure to rescue after major surgical procedures [1]. Sarcopenia is degenerative loss of skeletal muscle mass and strength. It is a key component of physical frailty and is associated with poorer post-surgical outcomes due to decreased patient strength and vitality.

Full description

This study seeks to examine whether the SARS-CoV-2 (COVID-19) pandemic, an ongoing global health crisis that was declared a national emergency by the US Federal Government on March 13, 2020, has exacerbated both frailty and sarcopenia in a population of liver transplant candidates.

Enrollment: 208 estimated patients

Sex: All

Ages: 18 to 75 years old

Volunteers: No Healthy Volunteers

Inclusion criteria

• Age 18 years and older Underwent pre-transplant frailty assessment (PFA) at MDMC

Exclusion criteria

• Not a patient at Liver Institute at Methodist Dallas